Liquidia’s YUTREPIA launch continues to expand rapidly as the company says the overall inhaled prostacyclin category has grown nearly 40% since the treatment entered the market, with YUTREPIA capturing an increasing portion of that growth.
YUTREPIA generated approximately $170.4 million of net product sales during the second quarter, representing a 31% increase from the first quarter. The sequential increase reflects continued adoption of the therapy following its June 2025 commercial launch and has quickly turned YUTREPIA into the primary driver of Liquidia’s revenue growth.
Between the product’s June 2025 launch and July 31, 2026, Liquidia recorded approximately 5,900 unique patient prescriptions and treated more than 5,000 patients. The company believes the expanding patient base demonstrates growing physician and patient acceptance of YUTREPIA within the inhaled prostacyclin market.
Management also pointed to growth in the broader category rather than simply share shifts among existing treatments. Liquidia said the inhaled prostacyclin market has expanded by nearly 40% since YUTREPIA launched, suggesting the product may be helping increase overall treatment utilization while simultaneously gaining market share.
The commercial ramp has significantly changed Liquidia’s financial profile. Second-quarter net income reached $74.7 million, while adjusted EBITDA increased to $96.3 million. The period represented the company’s fourth consecutive quarter of increasing profitability, a notable shift for a biotechnology company that historically invested heavily in clinical development ahead of commercialization.
Liquidity has strengthened alongside profitability. Cash and cash equivalents increased by $61.4 million from the first quarter, giving Liquidia additional financial flexibility to support commercial activities and fund the next stage of its clinical development program.
At the same time, Liquidia is pursuing a much broader strategy around inhaled treprostinil rather than relying exclusively on the current YUTREPIA opportunity. The company now has 10 studies supporting YUTREPIA and L606 across existing indications and potential new uses, creating multiple opportunities to expand the addressable patient population over time.
L606 is an extended-release inhaled treprostinil formulation designed for twice-daily administration. The program is being evaluated in the global pivotal Re-Spire trial for pulmonary hypertension associated with interstitial lung disease, or PH-ILD. Liquidia has begun activating clinical sites and enrolling patients in the study.
The company believes its experience commercializing YUTREPIA, including its emphasis on dose flexibility and tolerability, can support the broader development strategy. If successful, the additional studies could extend Liquidia’s inhaled treprostinil franchise into new patient populations while building on the commercial infrastructure already established for YUTREPIA.
KEY QUOTES:
“The inhaled category has grown almost 40% since launch, and YUTREPIA has captured an ever-increasing share of that growth.”
“Having reset the bar for tolerability and dose flexibility with YUTREPIA, we are excited to have begun site activation and enrollment in Re-Spire.”
Dr. Roger Jeffs, CEO of Liquidia
